Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

r of 2007, Amicus successfully completed a series of Phase I clinical studies of AT2220 in healthy volunteers. AT2220 is an orally available small-molecule pharmacological chaperone targeting the enzyme deficient in people living with Pompe disease. These studies demonstrated that AT2220 was generally safe and well-tolerated at all doses tested and that there were no drug-related serious adverse events. Amicus expects to report on these data at the ACMG conference in March along with the results of an additional clinical ex vivo response study designed to test the responsiveness of various Pompe mutations to AT2220.

"The data from these Phase 2 trials of Amigal and Plicera are part of an expanding body of scientific and clinical evidence that we are building through rigorous studies to demonstrate that many patients with Fabry, Gaucher and Pompe disease may be successfully switched from ERT to a pharmacological chaperone," noted John Crowley.

Other Protein Folding and Stabilization Programs:

In 2008, Amicus expects to accelerate its investments in research and development to better understand the potential for using pharmacological chaperones to treat a range of human genetic diseases that could benefit from improved protein folding and stabilization.

The company's advanced pre-clinical program in Parkinson's disease, funded in part by a grant from the Michael J. Fox Foundation, will continue with the potential to initiate clinical studies in 2008. In the fourth quarter of 2007, the company announced pre-clinical results which further support a biochemical link between the GCase enzyme and the accumulation of alpha- synuclein, a protein believed to play a key role in Parkinson's disease. Furthermore, in an animal model Amicus showed preliminary pre-clinical results that for the first time demonstrated that administration of a pharmacological chaperone can lead to reduction of alpha-synuclein aggregates in the brain. These results were fir
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Davis, California (PRWEB) January 22, 2015 ... of Accelerator Mass Spectrometry (AMS) services to the pharmaceutical ... PhD has joined the company in the position of ... 30 years of broad and valuable experience in drug ...
(Date:1/22/2015)... January 21, 2015 Cambridge Semantics, the leading ... today announced that 2014 was a record-breaking year across the ... of the Anzo Smart Data Platform and our Smart Data ... insights from diverse data which led to record growth for ...
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... , SAN DIEGO, Sept. 3 Gen-Probe Incorporated (Nasdaq: ... conferences: , , , Baird,s 2009 Health ... , Thomas Weisel Partners, Healthcare Conference 2009 in Boston at ... Stanley Global Healthcare Unplugged Conference in New York at 8:35 a.m. ET on September ...
... ... detection, diagnostics capabilities , ... Argonne, IL (PRWEB) September 3, 2009 -- Researchers at the ... improve the stability of antibodies. The technique could lead to better biosensors, disease ...
... NEW YORK, Sept. 3 Reportlinker.com announces that a new market research ... Proteomics: Technologies and Global Markets , , ... REPORT HIGHLIGHTS , , * ... in 2008 to an estimated $7.9 billion in 2009 and $19.4 billion ...
Cached Biology Technology:Gen-Probe to Webcast Four Upcoming Investor Presentations 2Argonne Researchers Develop Method that Aims to Stabilize Antibodies 2Argonne Researchers Develop Method that Aims to Stabilize Antibodies 3Argonne Researchers Develop Method that Aims to Stabilize Antibodies 4Reportlinker Adds Proteomics: Technologies and Global Markets Report 2Reportlinker Adds Proteomics: Technologies and Global Markets Report 3Reportlinker Adds Proteomics: Technologies and Global Markets Report 4Reportlinker Adds Proteomics: Technologies and Global Markets Report 5Reportlinker Adds Proteomics: Technologies and Global Markets Report 6Reportlinker Adds Proteomics: Technologies and Global Markets Report 7Reportlinker Adds Proteomics: Technologies and Global Markets Report 8Reportlinker Adds Proteomics: Technologies and Global Markets Report 9Reportlinker Adds Proteomics: Technologies and Global Markets Report 10Reportlinker Adds Proteomics: Technologies and Global Markets Report 11Reportlinker Adds Proteomics: Technologies and Global Markets Report 12Reportlinker Adds Proteomics: Technologies and Global Markets Report 13Reportlinker Adds Proteomics: Technologies and Global Markets Report 14Reportlinker Adds Proteomics: Technologies and Global Markets Report 15Reportlinker Adds Proteomics: Technologies and Global Markets Report 16Reportlinker Adds Proteomics: Technologies and Global Markets Report 17Reportlinker Adds Proteomics: Technologies and Global Markets Report 18Reportlinker Adds Proteomics: Technologies and Global Markets Report 19Reportlinker Adds Proteomics: Technologies and Global Markets Report 20Reportlinker Adds Proteomics: Technologies and Global Markets Report 21
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ...
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming the ... at international borders. Over the past decade, ePassports, biometric ... to self process through border control via eGates and ... of airports, seaports, and land borders across the globe. ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... of functional, stable blood vessels at the site of ... the Georgia Institute of Technology have been able to ... "This study shows that bio-artificial materials are suitable ... on the study Andrs Garca, professor and Woodruff Faculty ...
... , , MILPITAS, Calif., Dec. 21 Cermetek Microelectronics, ... V.22bis modem module (2400 bits per second), is the first ... medical equipment safety. Cermetek has targeted the CH24606 as a ... for less than $15 in 1000 piece quantities. , Aside ...
... supposedly used it to guide the construction the Pyramids. The ... on it. Fictional Harvard symbologist Robert Langdon tried to unravel ... "It" is the golden ratio, a geometric proportion that ... the eye and has been the root of countless mysteries ...
Cached Biology News:Bioengineered materials promote the growth of functional vasculature, new study shows 2Bioengineered materials promote the growth of functional vasculature, new study shows 3Cermetek Introduces Medically Approved Modem Module 2Mystery of golden ratio explained 2
... T1 Thermocycler provides high speed and excellent ... with a TGradient Thermocycler can be run ... with a silver block for 48 or ... well plates or in-situ applications are available. ...
SDS-OutT SDS Precipitation Reagent...
Designed for use with the Agencourt SprintPrep 384 kit and all MCPrep reagent kits. Used with flat bottom 96-well microplates such as deep well plates used to culture bacteria....
... Ideal for staining westerns and includes stickers ... Pour spouts in each corner facilitate pouring ... be used for identification. Lid is designed ... for staining several gels simultaneously. Lid also ...
Biology Products: